Stocks and Investing
Stocks and Investing
Thu, November 2, 2017
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lewis Maintained (ZBH) at Buy with Decreased Target to $136 on, Nov 2nd, 2017
David Lewis of Morgan Stanley, Maintained "Zimmer Biomet Holdings, Inc." (ZBH) at Buy with Decreased Target from $146 to $136 on, Nov 2nd, 2017.
David has made no other calls on ZBH in the last 4 months.
There are 4 other peers that have a rating on ZBH. Out of the 4 peers that are also analyzing ZBH, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kyle Rose of "Canaccord Genuity" Downgraded from Strong Buy to Hold on, Friday, July 28th, 2017
These are the ratings of the 3 analyists that currently disagree with David
- Jennie Tsai of "Gabelli & Co." Initiated at Strong Buy on, Thursday, August 24th, 2017
- Richard Newitter of "Leerink Swann" Maintained at Buy with Increased Target to $146 on, Friday, July 28th, 2017
- Christopher Pasquale of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, July 12th, 2017